AbbVie Inc. buy Snowman
Start price
16.12.21
/
50%
€115.90
Target price
16.03.22
€120.00
Performance (%)
23.37%
End price
16.03.22
€142.98
Summary
This prediction ended on 16.03.22 with a price of €142.98. The BUY prediction by Snowman finished with a performance of 23.37%. Dividends of €1.23 are taken into consideration when calculating the performance. Snowman has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AbbVie Inc. | -0.909% | -0.909% | 6.410% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% |
Comments by Snowman for this prediction
In the thread AbbVie Inc. diskutieren
Buy mit Kursziel 120,0
In the thread Trading AbbVie Inc.
Die von Snowman gewählte maximale Laufzeit wurde überschritten